Ombrabulin Hydrochloride

N/A

Report date: 2022/09/09 17:54:36
NME

Base Information

Drug NameOmbrabulin Hydrochloride
Drug Alias Nameombrabulinum奥拉布林ombrabulina昂雷布林奥瑞布林 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungSarcoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[22] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAjinomoto Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiSanofi-Aventis Recherche & Developpement
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungSarcoma +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG